<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Anbio Biotechnology Class A Ordinary Shares — News on 6ix</title>
<link>https://6ix.com/company/anbio-biotechnology-class-a-ordinary-shares</link>
<description>Latest news and press releases for Anbio Biotechnology Class A Ordinary Shares on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 17 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/anbio-biotechnology-class-a-ordinary-shares" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a2ae78dffbe2df109d7a.webp</url>
<title>Anbio Biotechnology Class A Ordinary Shares</title>
<link>https://6ix.com/company/anbio-biotechnology-class-a-ordinary-shares</link>
</image>
<item>
<title>Anbio Biotechnology to Participate in KeyBanc Capital Markets Healthcare Forum</title>
<link>https://6ix.com/company/anbio-biotechnology-class-a-ordinary-shares/news/anbio-biotechnology-to-participate-in-keybanc-capital-markets-healthcare-forum</link>
<guid isPermaLink="true">https://6ix.com/company/anbio-biotechnology-class-a-ordinary-shares/news/anbio-biotechnology-to-participate-in-keybanc-capital-markets-healthcare-forum</guid>
<pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
<description>FRANKFURT AM MAIN, Germany, March 17, 2026 (GLOBE NEWSWIRE) -- Anbio Biotechnology (NASDAQ: NNNN) ("Anbio" or the "Company"), a global diagnostic company in</description>
</item>
<item>
<title>Driving Veterinary Healthcare Forward: Anbio Showcases Diagnostic Portfolio at WSAVA 2025</title>
<link>https://6ix.com/company/anbio-biotechnology-class-a-ordinary-shares/news/driving-veterinary-healthcare-forward-anbio-034100478</link>
<guid isPermaLink="true">https://6ix.com/company/anbio-biotechnology-class-a-ordinary-shares/news/driving-veterinary-healthcare-forward-anbio-034100478</guid>
<pubDate>Thu, 09 Oct 2025 03:41:00 GMT</pubDate>
<description>Anbio Biotechnology participated in the 50th World Small Animal Veterinary Association Congress (WSAVA 2025), an international gathering that brought together veterinarians, researchers, and industry representatives from more than 100 countries. The event provided a platform for Anbio to present its veterinary diagnostic portfolio and exchange views with partners across global markets.</description>
</item>
<item>
<title>Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System</title>
<link>https://6ix.com/company/anbio-biotechnology-class-a-ordinary-shares/news/anbio-biotechnology-responds-global-outbreaks-chikungunya-rapid-test-and-new-15</link>
<guid isPermaLink="true">https://6ix.com/company/anbio-biotechnology-class-a-ordinary-shares/news/anbio-biotechnology-responds-global-outbreaks-chikungunya-rapid-test-and-new-15</guid>
<pubDate>Fri, 08 Aug 2025 04:00:00 GMT</pubDate>
<description>Covering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics for timely outbreak detection</description>
</item>
<item>
<title>Anbio Biotechnology to Showcase Global Diagnostic Innovations at Three Major May Exhibitions</title>
<link>https://6ix.com/company/anbio-biotechnology-class-a-ordinary-shares/news/anbio-biotechnology-showcase-global-diagnostic-innovations-three-major-may</link>
<guid isPermaLink="true">https://6ix.com/company/anbio-biotechnology-class-a-ordinary-shares/news/anbio-biotechnology-showcase-global-diagnostic-innovations-three-major-may</guid>
<pubDate>Thu, 15 May 2025 04:00:00 GMT</pubDate>
<description>Accelerating Expansion Across Human and Veterinary Health Through Innovation and Strategic Collaboration BRUSSELS, May 15, 2025 (GLOBE NEWSWIRE) -- Anbio</description>
</item>
<item>
<title>Anbio Biotechnology Announces Closing of Initial Public Offering</title>
<link>https://6ix.com/company/anbio-biotechnology-class-a-ordinary-shares/news/anbio-biotechnology-announces-closing-initial-145000580</link>
<guid isPermaLink="true">https://6ix.com/company/anbio-biotechnology-class-a-ordinary-shares/news/anbio-biotechnology-announces-closing-initial-145000580</guid>
<pubDate>Thu, 20 Feb 2025 14:50:00 GMT</pubDate>
<description>Frankfurt am Main, Germany, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Anbio Biotechnology (the “Company” or “Anbio”), a global diagnostic company dedicated to the advancement of medical technology and the provision of in vitro diagnostics products, today announced the closing of its initial public offering (the “Offering”) of 1,600,000 Class A ordinary shares (the “Class A Ordinary Shares”) at a public offering price of US$5.00 per Class A Ordinary Share. The Class A Ordinary Shares began trading on the</description>
</item>
<item>
<title>Anbio Biotechnology Announces Pricing of Initial Public Offering</title>
<link>https://6ix.com/company/anbio-biotechnology-class-a-ordinary-shares/news/anbio-biotechnology-announces-pricing-initial-231000710</link>
<guid isPermaLink="true">https://6ix.com/company/anbio-biotechnology-class-a-ordinary-shares/news/anbio-biotechnology-announces-pricing-initial-231000710</guid>
<pubDate>Tue, 18 Feb 2025 23:10:00 GMT</pubDate>
<description>Frankfurt am Main, Germany, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Anbio Biotechnology (the “Company” or “Anbio”), a global diagnostic company dedicated to the advancement of medical technology and the provision of in vitro diagnostics products, today announced the pricing of its initial public offering (the “Offering”) of 1,600,000 Class A ordinary shares (“the Class A Ordinary Shares”) at a public offering price of US$5.00 per Class A Ordinary Share. The Class A Ordinary Shares have been approved f</description>
</item>
</channel>
</rss>